NOVO NORDISK A/S

NYSE: NVO (Novo Nordisk A/S)

Kemas kini terakhir: 3 jam lalu

85.00

-18.44 (-17.83%)

  • 1H -17.83%
  • 5H -20.52%
  • 1B -19.09%
  • 6B -40.26%
  • Tahun Ke Tarikh -16.76%
  • 1T -17.24%
  • 5T 194.83%
Penutupan Terdahulu 103.44
Buka 82.72
Jumlah Dagangan 52,675,404
Purata Dagangan (3B) 6,077,740
Modal Pasaran 363,606,212,608
Harga / Pendapatan (P/E TTM) 28.52
Harga / Pendapatan (P/E Ke hadapan) 26.39
Harga / Jualan (P/S) 12.14
Harga / Buku (P/B) 27.10
Julat 52 Minggu
81.50 (-4%) — 148.15 (74%)
Tarikh Pendapatan 5 Feb 2025
Hasil Dividen (DY TTM) 1.70%
Margin Keuntungan 35.01%
Margin Operasi (TTM) 47.43%
EPS Cair (TTM) 2.98
Pertumbuhan Hasil Suku Tahunan (YOY) 21.40%
Pertumbuhan Pendapatan Suku Tahunan (YOY) 21.50%
Jumlah Hutang/Ekuiti (D/E MRQ) 47.27%
Nisbah Semasa (MRQ) 0.940
Aliran Tunai Operasi (OCF TTM) 118.22 B
Aliran Tunai Bebas Leveraj (LFCF TTM) 46.04 B
Pulangan Atas Aset (ROA TTM) 21.47%
Pulangan Atas Ekuiti (ROE TTM) 88.73%

Arah Aliran Pasaran

Jangka Pendek Jangka Sederhana
Industri Biotechnology (US) Bercampur Bercampur
Biotechnology (Global) Bercampur Bercampur
Stok Novo Nordisk A/S Menurun Menaik

AISkor Stockmoo

1.4
Konsensus Penganalisis 3.0
Aktiviti Orang Dalam NA
Volatiliti Harga 5.0
Purata Bergerak Teknikal 0.0
Osilator Teknikal -2.5
Purata 1.38

Saham Serupa

Stok Modal Pasaran DY P/E (TTM) P/B
NVO 364 B 1.70% 28.52 27.10
ADCT 190 M - - -
BHVN 4 B - - 11.75
RCUS 1 B - - 2.46
DNA 579 M - - 0.780
NUVB 946 M - - 1.80

With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Sektor Healthcare
Industri Biotechnology
Gaya Pelaburan Large Growth
% Dimiliki oleh Institusi 10.16%

Pemilikan

Nama Tarikh Syer Dipegang
Fayez Sarofim & Co 30 Sep 2024 12,217,118
Folketrygdfondet 30 Sep 2024 8,863,625
Gqg Partners Llc 30 Sep 2024 7,438,073
Polen Capital Management Llc 30 Sep 2024 6,854,659
Everett Harris & Co /Ca/ 30 Sep 2024 6,438,614
Julat 52 Minggu
81.50 (-4%) — 148.15 (74%)
Julat Harga Sasaran
156.00 (83%) — 160.00 (88%)
Tinggi 160.00 (Cantor Fitzgerald, 88.24%) Beli
Median 158.00 (85.88%)
Rendah 156.00 (BMO Capital, 83.53%) Beli
Purata 158.00 (85.88%)
Jumlah 2 Beli
Harga Purata @ Panggilan 111.79
Syarikat Tarikh Harga Sasaran Panggilan Harga @ Panggilan
Cantor Fitzgerald 06 Nov 2024 160.00 (88.24%) Beli 105.36
10 Oct 2024 160.00 (88.24%) Beli 117.53
BMO Capital 17 Oct 2024 156.00 (83.53%) Beli 118.22
  • 3M
Tarikh Jenis Butiran
20 Dec 2024 CNBC FDA approves Eli Lilly's weight loss drug Zepbound for sleep apnea, expanding use in U.S.
20 Dec 2024 Pengumuman Novo Nordisk A/S: CagriSema demonstrates superior weight loss in adults with obesity or overweight in the REDEFINE 1 trial
18 Dec 2024 Pengumuman The acquisition of Catalent by Novo Holdings, and the related acquisition by Novo Nordisk of three manufacturing sites from Novo Holdings, is completed
18 Dec 2024 CNBC Merck to develop weight loss pill from Chinese drugmaker in up to $2 billion licensing deal
16 Dec 2024 Pengumuman Novo Nordisk A/S - share repurchase programme
16 Dec 2024 Pengumuman Novo Nordisk invests DKK 8.5 billion in new production facility in Odense, Denmark
14 Dec 2024 Pengumuman Novo Nordisk A/S: The acquisition of Catalent by Novo Holdings, and the related acquisition by Novo Nordisk of three manufacturing sites from Novo Holdings, is cleared to close
12 Dec 2024 Pengumuman Novo Nordisk A/S: European regulatory authority adopts positive opinion for an update of the Ozempic® label to reflect risk reduction of kidney disease-related events
11 Dec 2024 CNBC Ro to offer lower-price vials of weight loss drug Zepbound by teaming up with Eli Lilly
09 Dec 2024 CNBC Prescription fills for weight loss drugs Zepbound and Wegovy more than doubled in 2024, GoodRx says
06 Dec 2024 Pengumuman The European Commission approves the acquisition of Catalent by Novo Holdings and the related acquisition by Novo Nordisk of three manufacturing sites from Novo Holdings
04 Dec 2024 CNBC Eli Lilly's Zepbound causes greater weight loss than Novo Nordisk's Wegovy in head-to-head trial
03 Dec 2024 Pengumuman Defiance Launches NVOX, the First 2X Leveraged Single-Stock ETF on Novo Nordisk
26 Nov 2024 CNBC Amgen says obesity drug caused up to 20% weight loss after a year, with no plateau
25 Nov 2024 Pengumuman Novo Nordisk A/S - share repurchase programme
13 Nov 2024 CNBC Amgen says no concerns around weight loss drug’s bone density data after stock falls
08 Nov 2024 Pengumuman Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
08 Nov 2024 Pengumuman Novo Nordisk A/S purchases B shares worth DKK 4,736 million from Novo Holdings A/S under the 2024 share repurchase programme
07 Nov 2024 Pengumuman Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
06 Nov 2024 Pengumuman Novo Nordisk's sales increased by 23% in Danish kroner and by 24% at constant exchange rates to DKK 204.7 billion in the first nine months of 2024
05 Nov 2024 Pengumuman Novo Nordisk A/S - share repurchase programme
01 Nov 2024 Pengumuman Novo Nordisk A/S: Semaglutide 2.4 mg demonstrates superior improvement in both liver fibrosis and MASH resolution in the ESSENCE trial
30 Oct 2024 CNBC Novo Nordisk's Ozempic and Wegovy now available in the U.S. after shortages, FDA says
30 Oct 2024 CNBC Eli Lilly stock tumbles after drug giant misses estimates and slashes profit guidance
23 Oct 2024 CNBC Novo Nordisk asks FDA to ban compounding pharmacies from making Ozempic, Wegovy copies
21 Oct 2024 Pengumuman Novo Nordisk A/S: Oral semaglutide demonstrates a 14% reduction in risk of major adverse cardiovascular events in adults with type 2 diabetes in the SOUL trial
21 Oct 2024 Pengumuman Novo Nordisk A/S - share repurchase programme
18 Oct 2024 Pengumuman Novo Nordisk A/S: Alhemo® recommended for European approval as first once-daily subcutaneous prophylactic treatment for people living with haemophilia A or B with inhibitors
08 Oct 2024 Pengumuman Novo Nordisk launches new initiative to prevent childhood obesity in disadvantaged urban communities
07 Oct 2024 Pengumuman Novo Nordisk A/S – Share repurchase programme
25 Sep 2024 CNBC Novo Nordisk's diabetes drug Ozempic may lower the risk of opioid overdoses, study says
24 Sep 2024 CNBC 'Stop ripping us off': Senate grills Novo Nordisk CEO on weight loss drug pricing
Papar semua
Hasil Dividen (DY TTM) 1.70%
Purata Hasil Dividen 5T 2.99%
Nisbah Pembayaran 46.73%
Jangkaan Pembayaran Dividen Seterusnya Apr 2025
Tarikh EX Tarikh Pengumuman Tarikh Pembayaran Perincian
16 Aug 2024 06 Aug 2024 26 Aug 2024 0.5126402 Tunai
22 Mar 2024 31 Jan 2024 02 Apr 2024 0.92985 Tunai
18 Aug 2023 10 Aug 2023 29 Aug 2023 0.8835613 Tunai
24 Mar 2023 02 Feb 2023 04 Apr 2023 1.1887415 Tunai
12 Aug 2022 04 Aug 2022 23 Aug 2022 0.5835507 Tunai
25 Mar 2022 02 Mar 2022 05 Apr 2022 1.022423 Tunai
16 Aug 2021 - 25 Aug 2021 0.5502889 Tunai
26 Mar 2021 - 07 Apr 2021 0.922122 Tunai
14 Aug 2020 06 Aug 2020 25 Aug 2020 0.5177774 Tunai
27 Mar 2020 06 Feb 2020 07 Apr 2020 0.7826048 Tunai
16 Aug 2019 10 Aug 2019 27 Aug 2019 0.449438 Tunai
22 Mar 2019 05 Feb 2019 02 Apr 2019 0.777006 Tunai
17 Aug 2018 09 Aug 2018 28 Aug 2018 0.462327 Tunai
23 Mar 2018 24 Mar 2018 03 Apr 2018 0.805982 Tunai
17 Aug 2017 - 29 Aug 2017 0.33589 Tunai
23 Mar 2017 - 04 Apr 2017 0.479369 Tunai
11 Aug 2016 - 23 Aug 2016 0.331026 Tunai
18 Mar 2016 - 30 Mar 2016 0.69943 Tunai
19 Mar 2015 - 31 Mar 2015 0.532885 Tunai
21 Mar 2014 - 02 Apr 2014 0.606122 Tunai
21 Mar 2013 - 02 Apr 2013 2.264307 Tunai
22 Mar 2012 - 03 Apr 2012 1.831902 Tunai
24 Mar 2011 - 05 Apr 2011 1.357901 Tunai
25 Mar 2010 - 07 Apr 2010 0.978615 Tunai
19 Mar 2009 - 31 Mar 2009 0.781532 Tunai
13 Mar 2008 - 25 Mar 2008 0.678462 Tunai
08 Mar 2007 - 20 Mar 2007 0.891779 Tunai
09 Mar 2006 - 21 Mar 2006 0.691753 Tunai
10 Mar 2005 - 22 Mar 2005 0.61725 Tunai
17 Mar 2004 - 29 Mar 2004 0.52096 Tunai
26 Mar 2003 - 07 Apr 2003 0.37647 Tunai
13 Mar 2002 - 25 Mar 2002 0.2848 Tunai
21 Mar 2001 - 02 Apr 2001 0.5681 Tunai
24 Mar 2000 - 06 Apr 2000 0.4672 Tunai
25 Mar 1999 - 06 Apr 1999 0.4182 Tunai
27 Mar 1998 - 08 Apr 1998 0.3051 Tunai
25 Apr 1997 - 07 May 1997 0.239 Tunai
01 May 1996 - 14 May 1996 0.1806 Tunai
Papar semua

Hasil Dividen Tahunan

Tahun Dividen Tahunan ($) Kekerapan/Tahun Hasil %
2024 1.44 2 1.70
2023 2.07 2 2.00
2022 1.61 2 2.37
2021 1.47 2 2.63
2020 1.30 2 3.72
2019 1.23 2 4.24
2018 1.27 2 5.51
2017 0.815 2 3.04
2016 1.03 2 5.75
2015 0.533 1 1.84
2014 0.606 1 2.86
2013 2.26 1 12.26
2012 1.83 1 11.22
2011 1.36 1 11.78
2010 0.979 1 8.69
2009 0.782 1 12.24
2008 0.678 1 13.20
2007 0.892 1 13.75
2006 0.692 1 16.54
2005 0.617 1 21.94
2004 0.521 1 19.20
2003 0.376 1 18.38
2002 0.285 1 19.71
2001 0.568 1 28.33
2000 0.467 1 26.40
1999 0.418 1 32.36
1998 0.305 1 22.94
1997 0.239 1 16.57
1996 0.181 1 19.32
Papar semua

Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.

Portfolio

AI Templat

Peringatan harga anda

Profil Risiko

| | | | |
Konservatif
Sederhana Konservatif
Sederhana
Sederhana Agresif
Agresif
Margin Keselamatan (EP)
Keuntungan Separa (TP1)
Keuntungan Sasaran (TP2)
Kerugian Maksimum (SL)

Penafian: Perkara di atas adalah untuk tujuan ilustrasi sahaja dan BUKAN nasihat pelaburan. Dapatkan nasihat daripada penasihat kewangan yang berkelayakan.

Harga Masuk (EP)

Ambil Untung 1 (TP1)

Ambil Untung 2 (TP2)

Henti Rugi (SL)

Julat 52 Minggu
 
52WL
 
52WH
SL
EP
TP1
TP2

Semua harga peringatan berada dalam julat harga 52 minggu

Keuntungan Nyata -
Keuntungan Tidak Nyata -
Dividen Diterima 2024 -
Jumlah Untung -
Pulangan Purata -
Kuantiti (Beli) -
Purata Harga (Beli) -
Kuantiti (Jual) -
Purata Harga (Jual) -
Tiada saham yang memenuhi kriteria anda